Prevalence of Severe Bleeding in COVID-19 Patients Treated With Higher Than Recommended Thromboprophylaxis Doses

Prevalence of Severe Bleeding in COVID-19 Patients Treated With Higher Than Recommended Thromboprophylaxis Doses (BLEEDING Study)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04380779

Acronym

BLEEDING

Enrollment

2430

Registered

2020-05-08

Start date

2020-04-13

Completion date

2020-10-13

Last updated

2020-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

The main objectives are: * To establish the prevalence of major bleeding in patients treated with higher than recommended thromboprophylaxis doses. * To identify variables associated to higher risk of bleeding.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients infected with COVID-19 treated with higher than recommended thromboprophylaxis doses. * Admission to hospital.

Exclusion criteria

* Patients treated with ECMO (Extracorporeal membrane oxygenation).

Design outcomes

Primary

Measure	Time frame	Description
Bleeding events and complications	30 days	Study endpoints are clinically recognized (and objectively confirmed) major and minor bleeding complications, and death.

Countries

Spain

Outcome results